The Magnetic Resonance group develops and tests new probes, instrumentation and techniques to better plan and assess cancer treatment.
Professor Kevin Harrington is Head of the Division of Radiotherapy and Imaging and studies the use of biologically targeted agents, in combination with treatments such as radiotherapy and chemotherapy, to target cancer cells selectively. He is a specialist in head and neck cancer and in melanoma, and a Fellow of the Royal College of Physicians and the Royal College of Radiologists.